Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Personalized Medicine
Personalized Medicine
Articles about personalized medicine on Value-Based Cancer Care. Learn how to utilize a patient's unique genetic makeup and environment to customize the patient's medical care and treatment.
Filter by Topic
Cancer Care
Cancer Drugs
Cancer Prevention
Cancer Quick Takes
Cancer Rehabilitation
Cancer Screening
Cervical Cancer
Chemotherapy
Clinical Research
Clinical Trials
Emerging Therapies
Genetic Testing
Hematologic Malignancies
Hormone Therapy
Immunotherapy
Multidisciplinary Care
Palliative Care
Pregnancy & Cancer
Prognostic Tests
Radiation Therapy
Radiotherapy in Focus
Sentinel Node Management
Solid Tumors
PET-Directed Approach Can Guide Radiation Therapy in Diffuse Large B-Cell Lymphoma
By
Phoebe Starr
Lymphoma
,
Solid Tumors
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—A positron emission tomography (PET)-directed approach after standard chemotherapy can guide the need for consolidation radiation therapy in patients with diffuse large B-cell lymphoma (DLBCL). This approach can spare patients from further treatments, such as salvage chemotherapy and stem-cell transplant, as well as unnecessary radiation therapy, according to a study presented at ASH 2017.
Read Article
Brentuximab Vedotin plus Nivolumab Yields High Complete Responses in Relapsed or Refractory Hodgkin Lymphoma
By
Chase Doyle
Lymphoma
,
Solid Tumors
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—Interim results from a phase 1/2 study of the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) have demonstrated a high overall response rate (ORR) in patients with relapsed or refractory Hodgkin lymphoma. According to data presented at ASH 2017, 83% of patients responded to the combination, which included a 62% rate among efficacy-evaluable patients.
Read Article
Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—As single-agent immunotherapies continue to show promising results, the challenge is now to determine which combination regimens with immunotherapies can improve outcomes. According to data presented at ASH 2017, 3 approaches are currently being explored.
Read Article
Novel TKI Leads to Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
By
Wayne Kuznar
Immunotherapy
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—A novel, third-generation, oral tyrosine kinase inhibitor (TKI), PF-114 mesylate, has antileukemic activity in heavily pretreated patients with chronic myeloid leukemia (CML), including those with
T315I
mutation, said Jorge E. Cortes, MD, Deputy Chair, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, at ASH 2017.
Read Article
CAR T-Cell Therapy Shows “Impressive” Results in Multiple Myeloma
By
Wayne Kuznar
Hematologic Malignancies
,
Immunotherapy
,
Multiple Myeloma
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—Although chimeric antigen receptor (CAR) T-cell therapies directed against the CD19 protein garnered much attention at ASH 2017, CAR T-cells targeting B-cell maturation antigen (BCMA), a protein expressed nearly universally on multiple myeloma cells, were found to be remarkably effective in patients with heavily pretreated multiple myeloma.
Read Article
Quizartinib Combinations Show High Activity in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—The combination of the investigational drug quizartinib plus azacitidine (Vidaza) or low-dose cytarabine has substantial activity in patients with myeloid leukemias and
FLT3
mutations.
Read Article
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—Treatment with ivosidenib, an IDH1 inhibitor, resulted in an objective response rate (ORR) of 41.6% in a phase 1 dose-escalation and expansion clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) and
IDH1
mutation.
Read Article
Mogamulizumab, Anti-CCR4 Antibody, Improves Survival in Patients with Advanced Cutaneous T-Cell Lymphoma
By
Charles Bankhead
Emerging Therapies
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—Mogamulizumab, a monoclonal antibody targeting CC chemokine receptor type 4 (CCR4), significantly reduced the risk for disease progression or death in patients with untreated cutaneous T-cell lymphoma (CTCL) compared with vorinostat (Zolinza), reported Youn H. Kim, MD, Director, Multidisciplinary Cutaneous Lymphoma Program, Stanford Medicine, California, at ASH 2017.
Read Article
CAR T-Cell Therapy Makes Significant Inroads in Lymphoma: Kymriah and Yescarta Show Durable Remissions
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—CD19-directed chimeric antigen receptor (CAR) T-cell therapy continues to show excellent and durable responses in patients with lymphoma who have no other treatment options. Two studies presented at ASH 2017 provide encouraging news for 2 new drugs, including long-term follow-up of the pivotal ZUMA-1 study of the CAR T-cell therapy axicabtagene ciloleucel (Yescarta), and primary results from the JULIET study of tisagenlecleucel (Kymriah).
Read Article
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Chicago, IL—The addition of the investigational CDK4/CDK6 inhibitor abemaciclib to fulvestrant (Faslodex) extended progression-free survival (PFS) by 7 months in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, reported George W. Sledge, Jr, MD, Professor, Medical Oncology, Stanford University Medical Center, Palo Alto, CA, who presented the results of a large study at the 2017 ASCO annual meeting.
Read Article
Page 8 of 35
3
4
5
6
7
8
9
10
11
12
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma